Connection

ANN LEEN to Viral Matrix Proteins

This is a "connection" page, showing publications ANN LEEN has written about Viral Matrix Proteins.
Connection Strength

0.662
  1. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001 Sep; 75(18):8649-59.
    View in: PubMed
    Score: 0.175
  2. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011 May; 13(5):518-22.
    View in: PubMed
    Score: 0.084
  3. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007 Oct 15; 110(8):2838-45.
    View in: PubMed
    Score: 0.065
  4. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107.
    View in: PubMed
    Score: 0.063
  5. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol. 2005 Sep 15; 175(6):4137-47.
    View in: PubMed
    Score: 0.058
  6. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother. 2004 Jul-Aug; 27(4):317-27.
    View in: PubMed
    Score: 0.053
  7. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002 May 01; 99(1):93-9.
    View in: PubMed
    Score: 0.046
  8. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy. 2019 02; 21(2):212-223.
    View in: PubMed
    Score: 0.036
  9. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203.
    View in: PubMed
    Score: 0.026
  10. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 Jan; 14(1):7-11.
    View in: PubMed
    Score: 0.022
  11. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008 Sep; 31(7):665-74.
    View in: PubMed
    Score: 0.018
  12. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.